FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 240 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... April 17, 2019 FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... March 27, 2025 Mom Credits Baby with Saving Her Life After She was Diagnosed... May 27, 2021 Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of... February 2, 2022 Load more HOT NEWS Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... The team tackling the serious side effects of cancer treatment in...
